AFA. A. Firstov

A. A. Firstov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. A. Firstov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of the frequency and risk indicators of developing acute pancreatitis after gastrectomy

    by E. A. Toneev, E. A. Keshyan, D. I. Nuretdinov, A. A. Martynov, A. V. Zhynov, A. A. Firstov

    INTRODUCTION. Surgical intervention remains the only effective treatment for gastric cancer. Despite advances in surgical techniques, tissue dissection and coagulation methods, and the quality of postoperative intensive care, the incidence of early complications remains considerably high. One of the most serious postoperative complications is acute pancreatitis, which significantly prolongs hospital stay and may lead to unsatisfactory treatment outcomes. The OBJECTIVE was to determine the incidence and risk factors for the development of acute pancreatitis following gastrectomy. METHODS AND MATERIALS. From 01.01.2018 to 31.10.2023, a total of 198 patients with stage I–III gastric cancer underwent gastrectomy at the Ulyanovsk Regional Oncology Center (Database State Registration Certificate no. 2024622328). Statistically significant factors influencing the development of acute pancreatitis after gastrectomy were identified. RESULTS. The incidence of acute pancreatitis (AP) was 8 % (16 out of 198). Among the 16 patients with AP, 5 developed a grade B external pancreatic fistula. Statistical analysis revealed a significant difference in the incidence of acute pancreatitis depending on the T category. Intraoperative blood loss volume also had a significant impact on the development of acute pancreatitis. Risk indicators for AP included the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (nLR). The threshold value for PLR was 215.6, and for nLR – 15.5. Exceeding these values predicted the development of AP in the postoperative period. CONCLUSION. Significant risk factors for the development of AP are the tumor size and depth of invasion (T category) and intraoperative blood loss exceeding 500 ml. Elevated serum amylase, PLR, and nLR levels on the first postoperative day, in the absence of other inflammatory signs, should be considered potential indicators of AP.


  • Open Access

    Results of treatment of two patients with MALT lymphoma

    by E. A. Toneev, I. B. Chigireva, R. F. Shagdaleev, A. A. Firstov, R. V. Ureneva, M. O. Pavlov, E. V. Martynova

    Introduction. MALT lymphoma is a rare histological type of malignant lung disease that develops from lymphoid tissue. This type of lymphoma belongs to the non-Hodgkin lymphomas. Given the lack of a standardized treatment protocol for patients with pulmonary MALT lymphoma, this study presents a case observation of the treatment of this disease. Each case observation is crucial for establishing a unified treatment strategy.Aim. To demonstrate the effectiveness of comprehensive treatment in two patients with pulmonary MALT lymphoma.Methods. This study presents two clinical cases of successful treatment of patients with MALT lymphoma at the regional clinical oncological dispensary in Ulyanovsk. The authors present their observations and describe the treatment regimens used. One patient underwent a tumor biopsy, which was inconclusive. Given the non-specific clinical presentation and the CT findings of a mass in the right lung with an undetermined histogenesis, as well as mediastinal involvement, surgical intervention was indicated for the morphological diagnosis of the lung mass. In both cases, targeted support with Rituximab was included in the treatment regimen. One case involved five courses of R-B therapy without progression, while in the other case, targeted therapy is planned as the next step after polychemotherapy.Conclusions. MALT lymphoma is a rare nosological form. According to the authors, the most optimal treatment method is a combined approach, which includes surgical treatment, polychemotherapy, and subsequent targeted therapy.

  • Open Access

    Small cell cancer of the esophagus, treatment outcomes of a rare histological type

    by E. A. Toneev, A. A. Firstov, D. I. Nuretdinov, E. Yu. Savenko, E. P. Anokhina, A. A. Martynov, Yu. A. Karabanova

    Purpose: To demonstrate treatment outcomes in two patients with small cell esophageal cancer. Cases reports. Patient M. was assigned to receive polychemotherapy (PC H) composed of etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days, followed by chemoradiotherapy (CRT). The patient received 1 cycle of PCT , which was well tolerated. Then, the patient received a cycle of 3D-conformal radiation therapy concurrently with 2 cycles of chemotherapy: etoposide 120 mg/m2 + cisplatin 80 mg/m2. Chemoradiotherapy was well tolerated. Dysphagia regression to grade I was observed. Currently, the patient continues to receive treatment (etoposide 100 mg/ m2 intravenously on days 1–3 + cisplatin 80 mg/m2 on day 1, every 21 days for 6 cycles and lanreotide 120 mg subcutaneously, every 28 days) and tolerates it well. Patient A. was assigned to receive PCT with etoposide 120 mg/m2 + cisplatin 80 mg/m2. After 4 cycles of PCT , the follow-up CT images revealed disease progression (enlarged retroperitoneal lymph nodes). The patient underwent external bean radiation therapy to the primary tumor. Radiotherapy was relatively well tolerated. The patient underwent the course of radiation therapy relatively satisfactorily. Due to the progression of the disease, symptomatic treatment was assigned. The patient died 9 months after diagnosis. Conclusion. Small cell carcinoma of the esophagus is a rare histological type with poor prognosis. Concurrent platinum-based chemoradiotherapy allows achievement of stable disease and disease control.

  • Open Access

    Results of combined and chemoradiation treatment of patients with thoracic esophageal cancer according to the data of the regional cancer center

    by E. A. Toneev, О. V. Pikin, Н. В. Деньгина, A. B. Ryabov, A. A. Мartynov, А. V. Galchin, D. N. Isaev, A. A. Firstov, D. D. Prohorov

    Background. esophageal cancer (ec) is one of the most aggressive malignancies of the gastrointestinal tract. chemoradiation therapy is the standard of care for locally advanced ec.The purpose of the study was to evaluate the efficacy of chemoradiation therapy given alone and in combination with surgery in patients with thoracic esophageal cancer.Material and Methods. From January 1, 2012 to december 31, 2021, a total of 940 patients with thoracic esophageal cancer were registered in the regional cancer registry, of which 178 patients were selected for concurrent chemoradiotherapy (CRT) at clinical stages I–III. thirty seven thoracic esophageal cancer patients who received CRT and required treatment interruption due to complications were not included in our analysis. The final analysis included 141 patients.Results. 37 (20.7 %) patients were unable to complete treatment due to intolerance and the development of severe complications of CRT. Hematological toxicity of grade 3-4 was noted in 21 patients (14.8 %). Non-hematological complications of grade 2-4 were noted in 109 patients (77.3 %). The 5-year relapse-free survival rates in patients undergoing and non-undergoing to surgery were 23.0 and 25.0 %, respectively (p=0.018). Overall 5-year survival rates were 24 and 27 %, respectively (p=0.020). The rate of pathological complete response (pcR) was 43.5 % (in 20 of 46 patients who underwent surgery after CRT). The median survival time in patients with clinical complete response (ccR) was 24.0 months and the median survival time in patients with pcR was 29.0 months. The 3-year survival rates were 21 and 45 %, respectively (p=0.050).Conclusion. The combination of chemoradiotherapy and surgery in patients with thoracic esophageal cancer demonstrated an increase in overall survival in our study. if there is a complete clinical response to CRT and contraindications for surgery or the patient’s refusal to undergo surgery, it is advisable to use the “wait & watch” tactic.